Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001999371-25-019650
Filing Date
2025-12-05
Accepted
2025-12-05 16:23:32
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 6617
2 SCHEDULE A ex99.htm EX-99 23071
  Complete submission text file 0001999371-25-019650.txt   31897
Mailing Address 79 NEW OXFORD STREET LONDON United Kingdom
Business Address 79 NEW OXFORD STREET LONDON United Kingdom 44 20 8047 5000
GSK plc (Filed by) CIK: 0001131399 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13D/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address FRIEDRICH-MIESCHER-STRASSE 15 TUBINGEN BADEN-WURTTEMBERG Germany 72076
Business Address FRIEDRICH-MIESCHER-STRASSE 15 TUBINGEN BADEN-WURTTEMBERG Germany 72076 49 7071 9883 0
CureVac N.V. (Subject) CIK: 0001809122 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91630 | Film No.: 251553248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)